

2024 Area of Interest for Atherosclerosis

Atherosclerosis Areas of Interest

Effective February 2024, the Investigator Studies Program Review Committee (MISP-RC) for Atherosclerosis will accept PRECLINICAL and CLINICAL (NON-INTERVENTIONAL) submissions within our current Areas of Interest (Aols). This is a competitive review process that will be conducted by the MISP Review Committee. Studies involving the use of MK-0616 will NOT be reviewed at this time.

Implementation Studies

- Studies evaluating approaches by specialty and primary care HCPs to Guideline Directed Medical Therapy and adherence to lipid-lowering therapies, including existing, approved PCSK9 inhibitors
- Diagnostic and digital health solutions to inform clinical decision-making, LDL-C monitoring, and patient adherence, including adult and pediatric HeFH patients

Epidemiology and Patient Characterization

- Studies that advance the understanding of unmet needs in patients with:
 - Coronary atherosclerosis, including CAD, PCI, ACS/post-MI
 - Cerebrovascular atherosclerosis such as stroke or TIA
 - Diabetes and related lipid management
 - Heterozygous Familial Hypercholesterolemia (HeFH)
 - Peripheral atherosclerosis, including PAD, carotid atherosclerosis, etc.
 - High-risk for ASCVD/subclinical atherosclerosis such as CAC
 - Disparities observed across specific patient populations
 - Other typically under-diagnosed/treated populations

Evaluation of the PCSK9 enzyme in non-cholesterol biological pathways